This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocel...
We've found 5 total result s for "Colorectal Neoplasms".
This study is open to people with newly diagnosed colorectal cancer. People who are scheduled for surgery can participate. People either get a medicine called BI 765063 combined with ezabenlimab or combined with pembrolizumab in preparation of the upcoming surgery. ...
Age: 18 years - 66+
Gender: All
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuxim...
- Neoplasms
- Ovarian Neoplasms
- Endometrial Neoplasms
- Uterine Cervical Neoplasms
- Kidney Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Prostatic Neoplasms
- Colorectal Neoplasms
- Stomach Neoplasms
- Breast Neoplasms
- Urinary Bladder Neoplasms
- Adenocarcinoma of Lung
- Melanoma
- Neoplasm Metastasis
- Carcinoma, Renal Cell
- Triple Negative Breast Neoplasms
- Head and Neck Neoplasms
- Lung Neoplasms
Age: 18 years - 66+
Gender: All
The primary objective is to confirm the specificity of a multi-target stool DNA test (mt-sDNA), Cologuard, in an average risk population, ages 45-49.
Age: 45 - 49 years
Gender: All
Compared to other racial groups, African Americans have the highest colorectal cancer (CRC) morbidity and mortality rates. Although colonoscopies can prevent CRC, nearly one third of African Americans have not received a screening colonoscopy within the recommended ti...
Age: 45 years - 66+
Gender: All